Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Lenz Therapeutics › Millennium Management LLC cut its LENZ stake below 5% (3.7%) Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Oct 21, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0001104659-26-117887
Data quality Verified: identifiers matched exactly
Around the same time Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Insider filing
Traded Oct 30 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 11, 2026 Company filing · Form 8-K · Results Reported its results What came next Oct 21, 2026 5% stake Millennium Management LLC reported a passive stake (13G) of 3.7% Oct 27, 2026 5% stake BlackRock Portfolio Management LLC reported a passive stake (13G) of 5.2% Oct 28, 2026 Company filing · Form 8-K · Results, Restructuring Announced job cuts, closures or a restructuring, and changed a top executive or board member (and 1 more item) “On October 28, 2026, the Company announced that Evert Schimmelpennink, the Company’s President and Chief Executive Officer (“CEO”), will transition from his roles as President and CEO effective December 1, 2026 (the “CEO Transition Date”), with Daniel Chevallard, the Company’s current Chief Financial Officer, to succeed him as Interim President and CEO as of such date.” Oct 29, 2026 Insider · 1 person Insiders: 3 sales (~$9.1M) Nov 2, 2026 5% stake RA Capital Management, L.P. filed an activist stake (13D) of 0.2% Nov 4, 2026 5% stake BML Investment Partners, L.P. reported a passive stake (13G) of 6.7% Nov 5, 2026 5% stake FMR LLC reported a passive stake (13G) of 2.0%